263 related articles for article (PubMed ID: 24351404)
1. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study.
Custodio A; Moreno-Rubio J; Aparicio J; Gallego-Plazas J; Yaya R; Maurel J; Higuera O; Burgos E; Ramos D; Calatrava A; Andrada E; López R; Moreno V; Madero R; Cejas P; Feliu J
Ann Oncol; 2014 Feb; 25(2):398-403. PubMed ID: 24351404
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms in cyclin H gene are associated with oxaliplatin-induced acute peripheral neuropathy in South Indian digestive tract cancer patients.
Palugulla S; Devaraju P; Kayal S; Narayan SK; Mathaiyan J
Cancer Chemother Pharmacol; 2018 Sep; 82(3):421-428. PubMed ID: 29936608
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy.
Custodio A; Moreno-Rubio J; Aparicio J; Gallego-Plazas J; Yaya R; Maurel J; Rodríguez-Salas N; Burgos E; Ramos D; Calatrava A; Andrada E; Díaz-López E; Sánchez A; Madero R; Cejas P; Feliu J
Mol Cancer Ther; 2014 Sep; 13(9):2226-37. PubMed ID: 24980946
[TBL] [Abstract][Full Text] [Related]
4. Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.
Zhao J; Li W; Zhu D; Yu Q; Zhang Z; Sun M; Cai S; Zhang W
Med Oncol; 2014 Jan; 31(1):802. PubMed ID: 24338217
[TBL] [Abstract][Full Text] [Related]
5. Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial).
Kanai M; Kawaguchi T; Kotaka M; Shinozaki K; Touyama T; Manaka D; Ishigure K; Hasegawa J; Munemoto Y; Matsui T; Takagane A; Ishikawa H; Matsumoto S; Sakamoto J; Saji S; Yoshino T; Ohtsu A; Watanabe T; Matsuda F
Ann Oncol; 2016 Jun; 27(6):1143-1148. PubMed ID: 27069012
[TBL] [Abstract][Full Text] [Related]
6. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients.
Won HH; Lee J; Park JO; Park YS; Lim HY; Kang WK; Kim JW; Lee SY; Park SH
Cancer; 2012 Jun; 118(11):2828-36. PubMed ID: 22020760
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.
Tougeron D; Mouillet G; Trouilloud I; Lecomte T; Coriat R; Aparicio T; Des Guetz G; Lécaille C; Artru P; Sickersen G; Cauchin E; Sefrioui D; Boussaha T; Ferru A; Matysiak-Budnik T; Silvain C; Karayan-Tapon L; Pagès JC; Vernerey D; Bonnetain F; Michel P; Taïeb J; Zaanan A
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26839356
[TBL] [Abstract][Full Text] [Related]
9. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.
Argyriou AA; Cavaletti G; Antonacopoulou A; Genazzani AA; Briani C; Bruna J; Terrazzino S; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Psaromyalou A; Angelopoulou A; Kalofonos HP
Cancer; 2013 Oct; 119(19):3570-7. PubMed ID: 23821303
[TBL] [Abstract][Full Text] [Related]
10. Neurotoxicity Outcomes in a Population-based Cohort of Elderly Patients Treated With Adjuvant Oxaliplatin for Colorectal Cancer.
Raphael MJ; Fischer HD; Fung K; Austin PC; Anderson GM; Booth CM; Singh S
Clin Colorectal Cancer; 2017 Dec; 16(4):397-404.e1. PubMed ID: 28434884
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry.
Park YS; Ji J; Zalcberg JR; El-Serafi M; Buzaid A; Ghosn M
Asia Pac J Clin Oncol; 2015 Dec; 11(4):334-42. PubMed ID: 26471890
[TBL] [Abstract][Full Text] [Related]
12. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
13. Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer.
Abrams TA; Brightly R; Mao J; Kirkner G; Meyerhardt JA; Schrag D; Fuchs CS
J Clin Oncol; 2011 Aug; 29(24):3255-62. PubMed ID: 21768462
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
15. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
Land SR; Kopec JA; Cecchini RS; Ganz PA; Wieand HS; Colangelo LH; Murphy K; Kuebler JP; Seay TE; Needles BM; Bearden JD; Colman LK; Lanier KS; Pajon ER; Cella D; Smith RE; O'Connell MJ; Costantino JP; Wolmark N
J Clin Oncol; 2007 Jun; 25(16):2205-11. PubMed ID: 17470850
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
17. Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70.
Lu CS; Chang PY; Chen YG; Chen JH; Wu YY; Ho CL
PLoS One; 2015; 10(9):e0138632. PubMed ID: 26382962
[TBL] [Abstract][Full Text] [Related]
18. Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy.
Tanishima H; Tominaga T; Kimura M; Maeda T; Shirai Y; Horiuchi T
Support Care Cancer; 2017 May; 25(5):1383-1389. PubMed ID: 27921224
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
Lonardi S; Sobrero A; Rosati G; Di Bartolomeo M; Ronzoni M; Aprile G; Massida B; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Barni S; Zagonel V; Maiello E; Rulli E; Labianca R;
Ann Oncol; 2016 Nov; 27(11):2074-2081. PubMed ID: 27573560
[TBL] [Abstract][Full Text] [Related]
20. The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study.
Takeshita E; Ishibashi K; Koda K; Oda N; Yoshimatsu K; Sato Y; Oya M; Yamaguchi S; Nakajima H; Momma T; Maekawa H; Tsubaki M; Yamada T; Kobayashi M; Tanakaya K; Ishida H
Surg Today; 2021 Aug; 51(8):1309-1319. PubMed ID: 33586034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
